What Myopia Progression Actually Is
What is myopia progression?
Myopia progression is the physical lengthening of the eyeball from front to back. As the eye grows longer, distant light focuses further in front of the retina, so the correction needed gets stronger. The blur is the symptom. The elongation is the condition, and it does not reverse.
A well-focused eye lands the image of a distant object exactly on the retina. In a nearsighted eye the distance to the retina is too long for the eye’s own focusing power, so the image lands short and distance vision blurs. Glasses move that image back onto the retina and restore clear sight, but they do not change the length that created the problem. That is why the number keeps climbing even though the correction works perfectly.
Most childhood myopia begins between six and twelve and progresses fastest in the two or three years after onset. It generally slows through the late teens and settles in the early twenties. The younger the onset, the more high-growth years remain and the higher the final prescription tends to be.
Parents are often told "it will stabilize eventually." That is usually true and beside the point. The question is not whether progression stops but where the eye is when it does. See Progressive Nearsightedness.
Axial Length, the Number Underneath the Prescription
Axial length is the front-to-back measurement of the eye in millimeters, taken by an optical biometer. It is the physical quantity myopia control is trying to influence, and everything else is downstream of it.
A typical adult eye measures roughly 23 to 24.5 millimeters. As a rough rule, each additional millimeter corresponds to something like two and a half to three diopters, so changes far too small to see are clinically enormous. A tenth of a millimeter repeated for eight years is not nothing.
We take a baseline reading for every child, then remeasure on a defined schedule. Four reasons we lean on this rather than refraction alone:
- It moves before the prescription does. Elongation is continuous, while a prescription is a rounded snapshot in quarter-diopter steps that can look flat for a year.
- It ignores focusing effort. A tired or over-focusing child measures differently on refraction. Biometry does not care how hard the child is squinting.
- It compares against known growth curves. Normative data exists by age, so a measurement can be judged rather than just recorded.
- It is the quantity tied to long-term risk. Published associations with later eye disease track with how long the eye is, not how thick the glasses are.
How the measurement is taken, what growth rates look like by age, and how we chart your child’s numbers is in Axial Length Monitoring.
Why Slowing Progression Matters
Higher myopia is not simply a stronger prescription. A longer eye is a stretched eye, and the tissues at the back of it are thinner. Across large population studies, the likelihood of several sight-threatening conditions rises continuously with myopia rather than switching on at a threshold.
- Retinal detachment. Risk rises substantially with degree. Treatable, especially when caught early, but an emergency where outcomes depend on speed.
- Myopic maculopathy. Stretching and thinning at the central retina. The one that concerns clinicians most, because it is often not repairable.
- Glaucoma. A higher rate in myopic eyes, and the optic nerve is harder to assess in a long eye, which can delay detection.
- Earlier cataract. Certain cataract types appear at younger ages, meaning surgery earlier in life rather than never.
The point is not to make myopia disappear. It is to change where a child lands. Finishing at four diopters instead of six means a lower lifetime risk profile. The specifics are in Long-Term Eye Health.
How Ortho-K Slows Progression
How does Ortho-K slow myopia in children?
Ortho-K flattens the central cornea overnight, correcting distance vision, and in doing so steepens the mid-periphery. That shape brings peripheral light to focus in front of the retina instead of behind it. This condition, peripheral myopic defocus, is the signal most closely associated with slower axial elongation.
Ordinary glasses create the opposite condition. They put the central image cleanly on the retina, but peripheral light in a myopic eye tends to land behind it. The working hypothesis, supported by animal and human research, is that the eye keeps growing toward that behind-the-retina signal. That may be why standard correction has no braking effect at all.
Ortho-K reverses that relationship as a byproduct of corneal reshaping. The child sees clearly in the center and spends every waking hour under the defocus signal associated with slower growth. No extra device, no drops, no daytime compliance.
The mechanism is explained with a diagram in Slowing Progression. The optics are in How Ortho-K Works and Ortho-K for Myopia.
What the Evidence Actually Shows
Ortho-K is one of the better-studied interventions in this field, examined in randomized and prospective controlled trials across several countries, commonly with two-year follow-up. Here is the honest shape of that literature.
- Direction is consistent. Studies comparing Ortho-K against single-vision glasses or soft contacts repeatedly find less axial elongation in the Ortho-K group. Very few well-conducted studies find no effect.
- Magnitude is meaningful but variable. Reported reductions cluster in a broad band rather than at one figure, differing by population, baseline age, and starting prescription. A trial average is not a promise to an individual.
- Effect is largest early. The gap between treated and untreated groups is widest in the first year or two. That is not the treatment failing, it reflects the untreated group also slowing as children age.
- Younger children have most to gain. They progress faster untreated, so absolute benefits are larger, and they need the intervention to run for more years.
- Rebound is not a prominent finding. Unlike some drug approaches, stopping Ortho-K has not been linked to a strong catch-up surge, though the evidence here is thinner.
When a child is not responding we say so and change the plan: lens parameters, an honest review of nightly wear, or a combination approach. More in Clinical Evidence and Realistic Expectations.
The Myopia Control Options, Compared
Ortho-K is one of several evidence-supported approaches, not automatically the right one.
| Approach | How it works | Daytime correction | Main trade-off |
|---|---|---|---|
| Overnight Ortho-K | Corneal reshaping gives peripheral myopic defocus all day | None needed | Nightly wear discipline and hygiene are non-negotiable |
| Soft dual-focus or multifocal lenses | Concentric treatment zones create defocus while worn | The lens itself | Handled by the child every day |
| Low-dose atropine drops | Pharmacological, mechanism not fully settled | Glasses or contacts still needed | Some children rebound after stopping |
| Myopia control spectacle lenses | Peripheral treatment zones built into the lens | The glasses themselves | Works only through the treatment zone |
| Single-vision glasses alone | Corrects blur, no effect on growth | The glasses themselves | The comparison group, not a strategy |
Combination therapy is also real: Ortho-K and low-dose atropine are sometimes used together for a child progressing quickly on either alone. Detail in Ortho-K vs Atropine and Ortho-K vs Soft Contacts.
How Our Myopia Control Program Works
The program is built around measurement rather than reassurance. You should be able to look at a chart and see whether your money is buying an outcome.
Three things distinguish this from a general practice adding Ortho-K to a service list. Every lens is designed from your child’s own topography, not a stock table. Axial length is measured with a biometer and remeasured on schedule. And progress is charted against expected growth, so "is it working" has an answer.
The visits are detailed on The Process, starting with consultation and candidacy and corneal topography.
Who Is a Candidate, and Who Is Not
Candidacy has two halves: whether the eye is suitable and whether the household is. We assess both.
- Strong candidates. Low to moderate myopia, regular astigmatism, healthy corneas and tear film, documented progression, and a family able to supervise a nightly routine.
- Often workable with planning. Higher prescriptions, moderate astigmatism, a younger child whose parent handles lenses, or a household needing the routine simplified.
- Usually not suitable. Myopia beyond what reshaping can correct, significant irregular astigmatism, active ocular surface disease, severe untreated allergy, or recurrent corneal problems.
- A hard stop. Any household where nightly cleaning will not reliably happen. Overnight wear with poor hygiene is the one scenario carrying real, avoidable risk.
Readiness in younger children is in Pediatric Ortho-K, the teenage version in Ortho-K for Teens, and safety in Is Ortho-K Safe.
What Myopia Control Costs
A candidacy consultation starts at $250 and is credited toward your program if you proceed. The complete Ortho-K fitting program starts at $1,800. The ongoing myopia control program, covering biometry, progress visits, written reporting, and plan adjustment, starts at $1,200 per year. You receive your exact figure in writing before you commit.
Set against that, a family correcting a progressive prescription buys new glasses most years, often a spare pair, sometimes sports eyewear. Those costs recur indefinitely and change nothing underneath. See Long-Term Value, Cost, and What Is Included.
Explore Myopia Control in Depth
Each page goes deeper on one part of the picture. For a single starting point, begin with childhood myopia management.
- Childhood Myopia Management. Risk factors, outdoor time, screens, and options compared for ages six to twelve.
- Axial Length Monitoring. How the measurement works, what growth rates mean, and how we chart it.
- Pediatric Ortho-K. Age readiness, handling, school and sports, and safety in children.
- Slowing Progression. Peripheral defocus explained plainly, and why response varies.
- Ortho-K for Teens. Compliance, independence, sport, and whether starting at fifteen is worth it.
- Long-Term Eye Health. The lifetime risk case, stated accurately.
- Progressive Nearsightedness. What counts as progression, and when to intervene.
- Parent Guide. A plain-language walkthrough for the parent deciding.